Updated May 2016: We are currently enrolling participants for the study entitled a Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS). This is an international Phase 3 study of tirasemtiv.
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
Update May 2016: The University of Michigan is a participating site in a nationwide clinical trial evaluating the use of the potassium channel modifier drug, Retigabine, in ALS patients. Researchers are beginning preparations to enroll patients in the near future.
Study press release: http://www.alsa.org/news/media/press-releases/trial-collaboration.html
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).
Read more at https://clinicaltrials.gov/ct2/show/NCT01709149
For questions on clinical trials at the University of Michigan, please email firstname.lastname@example.org